Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with
rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.